Capital Advisors Inc. OK Increases Holdings in OPKO Health, Inc. (NASDAQ:OPK)

Capital Advisors Inc. OK lifted its position in shares of OPKO Health, Inc. (NASDAQ:OPK - Free Report) by 133.3% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 350,000 shares of the biotechnology company's stock after purchasing an additional 200,000 shares during the period. Capital Advisors Inc. OK owned 0.05% of OPKO Health worth $581,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in OPK. Millennium Management LLC raised its holdings in OPKO Health by 85.3% in the 4th quarter. Millennium Management LLC now owns 4,588,526 shares of the biotechnology company's stock valued at $6,745,000 after acquiring an additional 2,112,382 shares in the last quarter. Lazard Asset Management LLC raised its holdings in OPKO Health by 143.6% in the 4th quarter. Lazard Asset Management LLC now owns 2,548,667 shares of the biotechnology company's stock valued at $3,746,000 after acquiring an additional 1,502,342 shares in the last quarter. Altshuler Shaham Ltd acquired a new position in OPKO Health in the 4th quarter valued at $2,082,000. Norges Bank acquired a new position in OPKO Health in the 4th quarter valued at $1,657,000. Finally, Two Sigma Investments LP raised its holdings in OPKO Health by 136.1% in the 4th quarter. Two Sigma Investments LP now owns 1,647,567 shares of the biotechnology company's stock valued at $2,422,000 after acquiring an additional 949,671 shares in the last quarter. 64.63% of the stock is owned by institutional investors and hedge funds.

OPKO Health Stock Down 0.7%

Shares of OPK stock traded down $0.01 during trading hours on Friday, reaching $1.35. The company had a trading volume of 1,758,039 shares, compared to its average volume of 3,867,082. OPKO Health, Inc. has a 12 month low of $1.21 and a 12 month high of $2.04. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.49 and a quick ratio of 2.28. The business has a fifty day simple moving average of $1.32 and a 200-day simple moving average of $1.49. The company has a market cap of $1.07 billion, a price-to-earnings ratio of -19.28 and a beta of 1.34.

OPKO Health (NASDAQ:OPK - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported ($0.10) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.03). The business had revenue of $149.90 million for the quarter, compared to analysts' expectations of $163.13 million. OPKO Health had a negative net margin of 5.66% and a negative return on equity of 2.85%. The business's revenue was down 13.7% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.12) earnings per share. On average, research analysts expect that OPKO Health, Inc. will post -0.25 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. JPMorgan Chase & Co. assumed coverage on OPKO Health in a report on Friday, April 25th. They set a "neutral" rating for the company. Barrington Research reissued an "outperform" rating and set a $2.25 price target on shares of OPKO Health in a report on Thursday, May 1st. Wall Street Zen cut OPKO Health from a "hold" rating to a "sell" rating in a report on Monday, May 5th. LADENBURG THALM/SH SH raised OPKO Health to a "strong-buy" rating in a research note on Tuesday. Finally, HC Wainwright reaffirmed a "buy" rating and set a $3.00 target price on shares of OPKO Health in a research note on Monday, April 7th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, OPKO Health currently has an average rating of "Moderate Buy" and a consensus price target of $2.75.

OPKO Health Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.